Market Overview

EOS imaging Achieves Its 100th Installation in the United States

Share:

Methodist Dallas Medical Center represents the 10th
installation in Texas

Milestones reflect growing adoption of EOS technology as a standard
of care in orthopedics

Regulatory News:

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI -
Eligible PEA - PME), the pioneer of 2D/3D imaging and data solutions for
orthopedics, today announced that the Methodist Dallas Medical Center
installed an EOS® system for low-dose, 2D/3D imaging of adult and
pediatric patients. The installation marks the 100th
system installed in the United States and the 10th system in
Texas.

Methodist Dallas Medical Center is part of the Methodist Health System
that operates 10 hospitals in Texas and more than two dozen Methodist
Family Health Centers and Medical Groups. The Methodist Dallas Medical
Center has developed a comprehensive Neurological and Spine program with
surgical staff specializing in back pain, tumors, stroke conditions,
spinal disorders and injuries as well as other neurological conditions.

"Achieving the 100th EOS® installation in
the U.S. and 10
th in the state of Texas
represent great milestones for our Company that reflect the adoption of
the EOS technology as a standard of care in all orthopedic points of
care, including the large and high growth community hospitals and
private practices market,"
said Marie Meynadier, CEO. "Addressing
the needs of these care providers in the U.S. has been an important part
of our commercial strategy in the last year, and we are happy to see
that our investments are prompting an acceleration of the EOS® adoption.
Our dynamics in the U.S., our largest and fastest growing market, have
reached an excellent pace and together with our momentum in all markets
provide confidence in our growth."

About EOS imaging

EOS imaging designs, develops and markets EOS®, a major innovative
medical imaging solution dedicated to osteo-articular pathologies and
orthopedics combining equipment and services and targeting a $2B per
year market opportunity. EOS imaging is currently present in 31
countries, including the United States under FDA agreement, Japan, China
and the European Union under CE labelling, through the over 250
installed EOS® platforms representing around one million patient exams
every year. Revenues were €37.1M in 2017, e.g. a +32% CAGR over
2012-2017.

For more information, please visit www.eos-imaging.com.

EOS imaging has been selected to integrate the EnterNext © PEA - PME
150 index, composed of 150 French, listed companies on the Euronext
markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN:
FR0011191766 - Ticker: EOSI

View Comments and Join the Discussion!